DISCLOSURE AGENDA. I have nothing to disclose

Similar documents
9/3/2013. Presentation Objective. Prescription Drug Abuse Statistics Prescription Drug Abuse Statistics. Pharmaceutical Drugs and the Environment

What is drug diversion?

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement.

AHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion

Mark W. Caverly, Chief Liaison and Policy Section

Crowe Healthcare Webinar Series

Drug Diversion from the Healthcare Workplace A Multi-Victim Crime. Keith H. Berge MD

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

University of Pittsburgh

6/19/2012. Disappearing Drugs. Disappearing Drugs: Protect Yourself from Diversion. Disappearing Drugs: Protect Yourself from Diversion

Review of Controlled Drugs and Substances Act

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System

Taos Alive. Improving a Community in Pain By Julie Martinez CPS

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

Changes to the Eighth Edition

Prescription Drug Abuse National Perspective

Secure Medicine Return Regulations King County, Washington

A Bill Regular Session, 2015 SENATE BILL 717

SUBJECT: Opioid Overdose and Intranasal Naloxone Training for Law Enforcement: Train the Trainer Session: Queens County October 17, 2014

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016

Today s Presenters. Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care

Vaccine Starter Kit Program FAQs

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies

INFORMATION BRIEF. Overview. Prescription Drug Abuse Among Young People

DEA: Combating the Supply

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Controlled Substances Program. For Academic Units

HUMA RESOURCES POLICY

Table of Contents Interim Report of the OxyContin Task Force, Newfoundland & Labrador, January 30, 2004

Prescription Drug Abuse Task Force Rx Report Card

The Wisconsin Prescription Drug Monitoring Program

Substance use and misuse

Commonwealth of Kentucky NASCIO Recognition Awards Nomination Category: Data, Information and Knowledge Management. ekasper

9/13/2017 DEA WHO WE ARE: Prescription Drug Abuse. American Association of Service Coordinators September 24-27, 2017 Disney s Coronado Springs Resort

Pennsylvania Prescription Drug Monitoring Program Trends,

Prescription Drug Impact in the Workplace

SECTION PRESCRIPTIONS

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

Statement Of. The National Association of Chain Drug Stores. For. United States Senate Caucus on International Narcotics Control.

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and

Drug Diversion and Safe Injections: Risks, Recommendations, & Resources. Oregon Public Health Division Healthcare-Associated Infections HAI Program

Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx

Controlled Substances: A survey of tools and resources required by hospital pharmacists

Overview of Current Medicine Take-Back Efforts

Barbara Brohl Executive Director & State Licensing Authority Colorado Department of Revenue

Opioid Use and Other Trends

North Carolina, like the rest of the nation, has been experiencing

NALOXONE RISK ASSESSMENT

Potential Solutions to Epidemic Substance Abuse in US and Europe

Drug Diversion Recognition and Prevention in a Hospital Setting. Natalie Tuttle PharmD, BCPS, DPLA University of Toledo Medical Center

Generation Rx: The Abuse of Prescription and Over-the-Counter Drugs

CDC s Approach to Addressing the Opioid Overdose Epidemic

Prescribing Controlled Substances and the PDMP

Ahsan U. Rashid, M.D., F.A.C.P.

ARKANSAS STATE UNIVERSITY GOVERNING PRINCIPLES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH

2017 PGIP Fact Sheet Electronic Prescribing of Controlled Substances (EPCS)

MEDICAL MARIJUANA USE

From Medicaid Transformation Approved Project Toolkit, June 2017

ACCG Mental Health Summit

Executive Summary Background: The Costs and Damage Caused by Drug Diversion

Implementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse

Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention

Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and

Prescription Opioid Overdose in Oregon: A public health perspective

National Strategies for Local Solutions

Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System

Use of Controlled Substances in Research.

Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting

NH State HAI Program Overview

Conflict of Interest Policy

Polling Question # 3. DISCLOSURE STATEMENT Pharmacy Immunizations How to Stay Competitive and in Compliance LEARNING OBJECTIVES

Treating Emergency Room Opioid Withdrawal with Buprenorphine

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017

Prescription Drugs: Issues in Treatment, Supervision and Case Management

PRESCRIBING GUIDELINES

Shannon Whitman Program Administrator Advancing Use of the MN PMP

Addressing the Harms of Prescription Drugs in Canada

The Opioid Epidemic: The State of the State

Confirm Limit--Level of detectable drugs in urine to confirm a positive test.

3/16/2018. Responding to a crisis. Opioid Overdose Prevention

Side Effects of the Prescription Drug Epidemic Health Care Providers and the DEA s Good Cop/Bad Cop Role

OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC:

Whatcom County. Opioid Abuse. Prevention & Response Plan

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling

C U S T O M E R D R I V E N. B U S I N E S S M I N D E D.

Coalition Strategies Across The Continuum of Care

Proper Medication Disposal

Employee Drug-Free Workplace Education

Combating Opiate Addiction

Washington State PMP Data Mapping Project

A Different Kind of Drug War. CINDY SANDERS Posted: Thursday, April 5, :07 pm. Providers Focus on Prescription Drug Addiction, Abuse

Although PDMPs are separately managed and maintained by each state or jurisdiction, the national network facilitates more uniformity among states.

Overview of ASHP Opioid Efforts

DRUG AND ALCOHOL POLICY

Transcription:

DRUG DIVERSION TIPS AND PRACTICES TO PREVENT, DETECT AND RESPOND TO POTENTIAL DIVERSION IN YOUR PHARMACY J O A N N E M Y H R E C P H T, B A D R U G D I V E R S I O N P R O G R A M M A N A G E R A L L I N A H E A L T H DISCLOSURE I have nothing to disclose AGENDA Define diversion and discuss various methods of diversion Discuss various legal implications/requirements Drug diversion statistics Outline components of a successful oversight program Describe an active Drug Diversion Program 1

DEFINITION Merriam-Webster The act of changing the direction or use of something Drug Enforcement Agency Diversion is the use of prescription drugs for recreational purposes Allina Health Any deviation that removes a prescription drug from its intended path from the manufacturer to the intended patient METHODS OF DIVERSION Doctor Shopping Traditional drug dealing Theft from pharmacies, homes, hospitals Acquiring prescription drugs via the internet without a physician visit Receiving drugs from friends/family Buying drugs from patient s after they leave clinics/pharmacies Faking legitimate illness(e.g. sports injury, anxiety) to obtain a prescription December 1, 2009 US Pharmacist Publication Prescription Drug Abuse: Strategies to Reduce Diversion DIVERSION IN THE NEWS A pharmacist in charge at a retail pharmacy had diverted Schedule II and III substances for a period of approximately three years. Minnesota A non-hospital employee posing as a nurse was stealing patients' painkillers while they were in their hospital rooms, watching, and also tampered with a machine that administers drugs, and cutting the line from the machine to the patient. Washington; Minnesota 2

DIVERSION IN THE NEWS A care provider had multiple narcotics wastes at unexplained times; signed out different medications at the same time, assigned drugs to patients other than his own, or charted them incorrectly. Pennsylvania Twice a week over a four-month period a care provider siphoned some of the controlled substance out of patients' IV drip bags. 25 patients contract a rare bacterial infection. -Minnesota LEGAL IMPLICATIONS Safety Patient Employee Quality outcomes Regulatory and financial - significant fines and penalties Walgreens - record settlement of $80m in June 2013 Revocation of DEA license entity and/or staff LEGAL REQUIREMENTS Controlled Substance Act of 1970 Food and Drug Administration Office of Criminal Investigation DEA State/Local Law Enforcement MN Board of Pharmacy Prescription Drug Monitoring Program MN Department of Health Other various professional organizations MN Board of Nursing 3

FEBRUARY 20, 2013 PRESS RELEASE CENTER FOR DISEASE CONTROL & PREVENTION 2010: Statistics on Causes of Death in the U.S. Cause of Death Number of Deaths Total Drug Overdoses 38,329 Car Crashes 35,498 Firearms 31,672 Total Drug Overdoses Pharmaceutical Drug Overdoses Prescription Opioid/Pain Reliever Overdoses 22,134 16,651 DATA FROM THE ANNUAL NATIONAL SURVEY ON DRUG USE AND HEALTH CONDUCTED BY THE SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION 30 25 20 15 10 5 0 Number of Americans aged 12 or older that reported the use of an illicit drug or medication in the past month 5 14 19.1 20.1 23.9 1993 2000 2004 2008 2012 Data in millions SPECIFIC ILLICIT DRUG DEPENDENCE OR ABUSE IN THE PAST YEAR AMONG PERSONS AGED 12 OR OLDER Marijuana Pain relievers Cocaine Tranquilizers Stimulants Heroin Hallucinogens Inhalanta Sedatives 0 1000 2000 3000 4000 5000 2012 Data from the annual National Survey on Drug Use and Health (NSDUH) conducted by the Substance Abuse and Mental Health Services Administration 4

CONTROLLED SUBSTANCES MOST ASSOCIATED WITH A THEFT OR LOSS EVENT hydrocodone Oxycodone hydromorphone morphine sulphate fentanyl National Survey on Drug Use and Health - 2012 MN STATISTICS From 2005 to 2011, there were 250 reports of theft or loss of controlled substances in hospitals and nursing homes There was a 352% increase in reports between 2006 (16*) and 2010 (52*) * Retail pharmacy thefts are not included in these numbers Taken from MN DOH website: according to data from the U.S. Drug Enforcement Administration (DEA). MINNESOTA COALITION In May 2011, the Minnesota Department of Health (MDH) and the Minnesota Hospital Association (MHA) invited a coalition of hospital, provider, law enforcement, licensing and other health care stakeholders to collaboratively address this important issue. The coalition completed its work in April 2012 for more information go to the MN Dept. of Heath website: www.health.state.mn.us/patientsafety/drugdiversion 5

COMPONENTS OF A SUCCESSFUL DRUG DIVERSION PROGRAM S Safety teams/organizational structure A Access to information/accurate reporting; monitoring; surveillance detection system F Facility expectations E Educate staff COMPONENTS OF A SUCCESSFUL DRUG DIVERSION PROGRAM STORAGE & SECURITY PROCUREMENT PRESCRIBING PREPARATION & DISPENSING ADMINISTRATION HANDLING WASTE MONITORING OF AND PROCESS IF DIVERSION IS SUSPECTED Excerpt from the Road Map http://www.mnhospitals.org/portals/0/documents/ptsafety/diversion/controlledsubstance-diversion-prevention-roadmap.pdf SO What Does a Drug Diversion Program Look Like? 6

ALLINA HEALTH BACKGROUND Large not-for profit systems serving MN and WI 26,405 employees; 5,000 associated and employed physicians; and more than 4,100 volunteers 12 hospitals 112,973 inpatient hospital admissions 1.2 million hospital outpatient admissions 23 hospital-based clinics 57 Allina Health clinics 3.3 million clinic visits 15 retail pharmacy sites 844,601 retail pharmacy prescriptions filled 3 ambulatory care centers 2013 Data DRUG DIVERSION PROGRAM TIMELINE Approved the development of a Drug Diversion Program Various action Plans created and implemented the Drug Diversion Program Manager Role 2011 2012 2013 2014 Key stake holders pulled together and work began Allina Health continues to invest in its Drug Diversion Program ALLINA HEALTH DRUG DIVERSION PROGRAM OVERVIEW Governance Oversight Strategy/Direction Drug Diversion Control Standards Risk Based Approach Assessments Proactive Monitoring Incident Response and Reporting Incident workflows Reporting Education All Employees Manager Tool kit 7

GOVERNANCE - OVERSIGHT Ethics Compliance and Oversight Committee (ECOC) Drug Diversion Steering Committee Drug Diversion Council GOVERNANCE STRATEGY/DIRECTION Conduct diversion risk assessment Create organizational control Standards Design control environment by area - Threshold Quantify risk; establish risk tolerance/appetite Current state or operational gap assessment Evaluate gaps; determine remediation; recommend Communicate, report; corrective action plans Follow up; periodic reassessment ALLINA BUSINESS AREAS Retail Pharmacies Clinics Emergency Medical Services IP Hospital Pharmacies Hospital Satellite Pharmacies OR with ADC (automated dispensing cabinets) OR with out ADC OR with combo 8

CONTROL STANDARDS Business Area (BA) Threshold Design the desired state through the risk-based application of applicable Standards and methods to a specific business area or clinical practice method Optimally position control environments Relative to business needs and diversion risk response Design might include less desirable Methods Necessary for measuring a gap by business area Threshold Gap (risk) = Most Desirable Method - Designed Method CONTROL STANDARDS User Access to Physical Areas, Devices and Business Applications Inventory Maintenance Safeguards of Physical Surroundings Safeguards of Inventory Storage Devices, Containers Inventory Item Safeguards Medication Orders and Filling Patient Administration Waste and Destruction Monitoring and Oversight STANDARD SUBCATEGORIES User Access to Physical Areas, Devices and Business Applications Access Authorization New Hires Access Management Employee Changes User Roles and Responsibilities Administration User Roles and Responsibilities Segregation of Duties Inventory Maintenance C2 Inventory Ordering Authorization C3-C5 Inventory Ordering Authorization Inventory Ordering DEA Form 222 Safeguards Inventory Purchasing Inventory Item Levels 9

FINAL STANDARD LAYOUT RISK BASED APPROACH ASSESSMENTS Operational Gap Assessment CSA Questionnaire to capture Current State One question written for each Standard Business area questionnaire extracted based on Threshold selections User-friendly format; clear instructions Individual, group or facilitated sessions Content was lengthy, high-level reading Objective was to gather the how, rather than if ASSESSMENT CRITERIA Severity - How much harm will occur to a patient because of this? Likelihood of Occurrence - How likely is it that diversion by this method will occur? Detection & Response - How likely is it that the failure will be detected and we ll be able to identify the cause? Control Maturity - The current state of controls designed to minimize the likelihood that the failure will jeopardize our ability to achieve business objectives. 10

Standards Value Scale RISK How much risk is management willing to accept in pursuit of its mission to deliver safe, high-quality patient care? Practical considerations for operational effectiveness and efficiencies Physical limitations of the work environment Developed a Standards Value Scale TOLERANCE / APPETITE Business Area Threshold The numeric value (sum of the applicable Standards control activities) attributed to the optimally positioned controlled substance control environment for the business area relative to business needs and diversion risk response. Residual Risk Risk remaining after management determines the optimally positioned control environment for a business area Risk Appetite The amount of residual risk Allina is willing to accept in pursuit of its mission to deliver safe, high-quality patient care RISK/THRESHOLDS 100% Business Area Thresholds 80% 60% 40% Residual Risk Threshold 20% 0% AHP Clinics AHEMS IP PHARM SAT PHARM 11

Drug Diversion Control Standards Value Scale BUSINESS AREA CSA QUESTIONNAIRE SAMPLE EVALUATE RESULTS Council ensures consistent, risk-based approach across the organization Each Standard was classified Required Must evaluate and remediate risk Addressable Must evaluate risk and encourage remediation; or explain reason for not remediating Gaps present globally or location specific Gaps where remediation is not recommended Best balance of efficiency and cost Considers size and complexity of location RECOMMENDATIONS 1000 800 600 400 Initial State 12/2012 Current State 7/2014 Target 2013 200 0 ANW MCY UHI OWA 12

ALLINA HEALTH DRUG DIVERSION PROGRAM OVERVIEW PROACTIVE MONITORING PROACTIVE WORKFLOW 13

INCIDENT RESPONSE Step 1: Potential Drug Diversion event is identified and reported Step 2: Assess event and determine if there is a need to continue with full investigation Step 3: Pull team together, assess risk, Conduct Investigation Step 4: Evaluate findings, and Determine the Appropriate Level of Corrective Action if applicable Step 5: Review findings, implement and Report if applicable Step 6: close event and debrief CORE TEAM Core Team includes Site Pharmacy Leader Human Resources Manager Additional Ad-Hoc Members include both local and system resources Program Manager Compliance Risk Security Security Investigator Legal Labor Relations Communications Core Team Leader decided by site team *NOTE: The Core Team DOES NOT include the suspect, any witness or other front line staff member INCIDENT RESPONSE Tool Purpose is to help guide and ensure those critical first steps are addressed 14

INCIDENT WORKFLOWS INCIDENT WORKFLOWS ADDITIONAL WORKFLOWS 15

REPORTING - INCIDENT Regulatory Ensure required reporting occurs when applicable DEA BOP BON DOH if risk of Blood Born Pathogen exposure System Leadership where incident occurred Drug Diversion Program Manager Other System Office staff as needed Risk Compliance Legal HR System Senior leadership if applicable REPORTING - ASSESSMENT Significant gaps are clearly communicated to sitebased owners Draft report discussed with management Report template Executive summary Thresholds and residual risk for the business area High level summary of exposure areas Current state score and Target score Details of gap assessment and evaluation Appendixes describe the Program REPORTING - PROGRAM 16

EDUCATION Routine Developed an annual Drug Diversion Education module that each Allina Health employee is required to take Content is updated each year as needed All new Allina Health employees receive additional Drug Diversion education as part of their new employee orientation Content is updated as the Program expands Internal Drug Diversion Web page Various resources for employees Tip sheet on Drug Diversion Risks and Behaviors How to report suspected diversion EDUCATION Ad-Hoc Education Programs for key stake holders in each business area (Managers, HR, Risk, Quality, Pharmacy, Compliance) Created when: New tools are created Changes to reporting tools Changes to event response Internal Drug Diversion Web page Various resources for managers HR policies Program Information Manager Tool Kit Responsibilities Incident Response Procedure TOOLS FOR ALLINA HEALTH EMPLOYEES Allina intranet webpages: AKN Drug Diversion Page MyAllina Manager Toolkit MyAllina: Manager Resources Performance Drug Discrepancy/Diversion 17

WRAP UP Diversion will happen and it's all of our jobs to report suspected diversion to keep our patients, yourself and your coworkers safe. All sites that facilitate the use of controlled substances should have some level of diversion monitoring/detection activities occurring Response to a potential diversion event needs to be swift Investigation work needs to be timely Take advantage of the resources available MHA Roadmap QUESTIONS Thank You JoAnne.Myhre@allina.com 18